9-chloro-2,3-dimethoxyacridine | 58778-12-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 9-chloro-2,3-dimethoxyacridine
• CAS: 58778-12-4
• 化学式: C₁₅H₁₂ClNO₂
• 分子量: 273.719
• InChiKey: WDJQFWTUFXBNDF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  31.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  9-chloro-2,3-dimethoxyacridine 在 tetraphosphorus decasulfide 作用下， 以 N,N-二甲基丙烯基脲 为溶剂， 生成
  参考文献：
  名称：

  Structure–activity relationship study of acridine analogs as haspin and DYRK2 kinase inhibitors

  摘要：

  Haspin is a serine/threonine kinase required for completion of normal mitosis that is highly expressed during cell proliferation, including in a number of neoplasms. Consequently, it has emerged as a potential therapeutic target in oncology. A high throughput screen of approximately 140,000 compounds identified an acridine analog as a potent haspin kinase inhibitor. Profiling against a panel of 270 kinases revealed that the compound also exhibited potent inhibitory activity for DYRK2, another serine/threonine kinase. An optimization study of the acridine series revealed that the structure-activity relationship (SAR) of the acridine series for haspin and DYRK2 inhibition had many similarities. However, several structural differences were noted that allowed generation of a potent haspin kinase inhibitor (33, IC(50) <60 nM) with 180fold selectivity over DYRK2. In addition, a moderately potent DYRK2 inhibitor (41, IC(50) <400 nM) with a 5.4-fold selectivity over haspin was also identified. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.04.150
• 作为产物：
  描述：

  6-硝基藜芦酸甲酯 在 tris-(dibenzylideneacetone)dipalladium(0) 、 palladium 10% on activated carbon 、 水 、 氢气 、 caesium carbonate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 、 sodium hydroxide 、 三氯氧磷 作用下， 以 1,4-二氧六环 、 甲醇 、 水 为溶剂， 反应 52.0h， 生成 9-chloro-2,3-dimethoxyacridine
  参考文献：
  名称：

  [EN] TRICYCLIC COMPOUNDS AS HISTONE METHYL-TRANSFERASE INHIBITORS
  [FR] COMPOSÉS TRICYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS D'HISTONE MÉTHYLTRANSFÉRASES

  摘要：

  本公开提供了某些三环化合物，它们是组蛋白甲基转移酶G9a和/或GLP抑制剂，因此可用于治疗通过抑制G9a和/或GLP可治疗的疾病，如癌症和血红蛋白病（例如β地中海贫血和镰状细胞病）。还提供了含有这些化合物的药物组合物和制备这些化合物的方法。

  公开号：

  WO2019036377A1

文献信息

• Synthesis and preliminary cytotoxic activity of dimethoxy-acridines and dimethoxynitroacridines
  作者：A. Monge、F. J. Martínez-Crespo、L. Santamaría、S. Narro、A. López De Ceráin、E. Hamilton、A. J. Barker

  DOI：10.1002/jhet.5570310628

  日期：1994.11

  The preparation of a series of dimethoxy and dimethoxynitroacridines and their activity in oxic and hypoxic cells is reported. Anthranilic acids 1,4,14 were prepared according to the Ullmann condensation. 9-chloroacridines were obtained from anthranilic acids by refluxing in phosphorus oxychloride. The synthesis of two new acridine dimers 9,10 is described. Nitration of 9-chloro-2,4-dimethoxyacridine

  报道了一系列二甲氧基和二甲氧基硝基ac的制备及其在含氧和低氧细胞中的活性。根据乌尔曼缩合法制备邻氨基苯甲酸1,4,14。通过在氯氧化磷中回流，从邻氨基苯甲酸获得9-氯ac啶。描述了两个新的a啶二聚体9，10的合成。硝化9-氯-2，4-二甲氧基ac啶15，得到3-硝基异构体19。通过所有9-氯chloro啶的苯酚介导的偶联反应，获得了各自的9-（烷基氨基）ac啶。通过硝化17，制备了新的2,4-二甲氧基-3,7-二硝基ac啶21
• Borsche et al., Chemische Berichte, 1933, vol. 66, p. 1315,1316
  作者：Borsche et al.

  DOI：——

  日期：——
• TRICYCLIC COMPOUNDS AS HISTONE METHYL-TRANSFERASE INHIBITORS
  申请人：Global Blood Therapeutics, Inc.

  公开号：EP3668863A1

  公开（公告）日：2020-06-24
• US3936457A
  申请人：——

  公开号：US3936457A

  公开（公告）日：1976-02-03
• Structure–activity relationship study of acridine analogs as haspin and DYRK2 kinase inhibitors
  作者：Gregory D. Cuny、Maxime Robin、Natalia P. Ulyanova、Debasis Patnaik、Valerie Pique、Gilles Casano、Ji-Feng Liu、Xiangjie Lin、Jun Xian、Marcie A. Glicksman、Ross L. Stein、Jonathan M.G. Higgins

  DOI：10.1016/j.bmcl.2010.04.150

  日期：2010.6

  Haspin is a serine/threonine kinase required for completion of normal mitosis that is highly expressed during cell proliferation, including in a number of neoplasms. Consequently, it has emerged as a potential therapeutic target in oncology. A high throughput screen of approximately 140,000 compounds identified an acridine analog as a potent haspin kinase inhibitor. Profiling against a panel of 270 kinases revealed that the compound also exhibited potent inhibitory activity for DYRK2, another serine/threonine kinase. An optimization study of the acridine series revealed that the structure-activity relationship (SAR) of the acridine series for haspin and DYRK2 inhibition had many similarities. However, several structural differences were noted that allowed generation of a potent haspin kinase inhibitor (33, IC(50) <60 nM) with 180fold selectivity over DYRK2. In addition, a moderately potent DYRK2 inhibitor (41, IC(50) <400 nM) with a 5.4-fold selectivity over haspin was also identified. (C) 2010 Elsevier Ltd. All rights reserved.